Skip to main content
EMBO Molecular Medicine logoLink to EMBO Molecular Medicine
. 2017 Dec 1;9(12):1763. doi: 10.15252/emmm.201708507

Peroxisome proliferator‐activated receptor gamma (PPARγ) is central to the initiation and propagation of human angiomyolipoma, suggesting its potential as a therapeutic target

Oren Pleniceanu, Racheli Shukrun, Dorit Omer, Einav Vax, Itamar Kanter, Klaudyna Dziedzic, Naomi Pode‐Shakked, Michal Mark‐Daniei, Sara Pri‐Chen, Yehudit Gnatek, Hadas Alfandary, Nira Varda‐Bloom, Dekel D Bar‐Lev, Naomi Bollag, Rachel Shtainfeld, Leah Armon, Achia Urbach, Tomer Kalisky, Arnon Nagler, Orit Harari‐Steinberg, Jack L Arbiser, Benjamin Dekel
PMCID: PMC5709741  PMID: 29196313

Abstract

graphic file with name EMMM-9-1763-g001.jpg


The authors of the above research article have informed the journal that although the paper uses the official nomenclature PPARG to signify the peroxisome proliferator‐activated receptor gamma gene, the most prevalent term used in the literature is PPARγ. Therefore, the title, abstract, and keywords have been changed and now apply the latter term to improve searchability. The authors apologize for any inconvenience caused.


Articles from EMBO Molecular Medicine are provided here courtesy of Nature Publishing Group

RESOURCES